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Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdoma;
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ABSTRACT
African horse sickness virus (AHSV), an orbivirus in the Reoviridae family with nine different serotypes, causes devastating dis-
ease in equids. The virion particle is composed of seven proteins organized in three concentric layers, an outer layer made of VP2
and VP5, a middle layer made of VP7, and inner layer made of VP3 that encloses a replicase complex of VP1, VP4, and VP6 and a
genome of 10 double-stranded RNA segments. In this study, we sought to develop highly efficacious candidate vaccines against
all AHSV serotypes, taking into account not only immunogenic and safety properties but also virus productivity and stability
parameters, which are essential criteria for vaccine candidates. To achieve this goal, we first established a highly efficient reverse
genetics (RG) system for AHSV serotype 1 (AHSV1) and, subsequently, a VP6-defective AHSV1 strain in combination with in
trans complementation of VP6. This was then used to generate defective particles of all nine serotypes, which required the ex-
change of two to five RNA segments to achieve equivalent titers of particles. All reassortant-defective viruses could be amplified
and propagated to high titers in cells complemented with VP6 but were totally incompetent in any other cells. Furthermore,
these replication-incompetent AHSV particles were demonstrated to be highly protective against homologous virulent virus
challenges in type I interferon receptor (IFNAR)-knockout mice. Thus, these defective viruses have the potential to be used for
the development of safe and stable vaccine candidates. The RG system also provides a powerful tool for the study of the role of
individual AHSV proteins in virus assembly, morphogenesis, and pathogenesis.
IMPORTANCE
African horse sickness virus is transmitted by biting midges and causes African horse sickness in equids, with mortality reaching
up to 95% in naive horses. Therefore, the development of efficient vaccines is extremely important due to major economic losses
in the equine industry. Through the establishment of a highly efficient RG system, replication-deficient viruses of all nine AHSV
serotypes were generated. These defective viruses achieved high titers in a cell line complemented with VP6 but failed to propa-
gate in wild-type mammalian or insect cells. Importantly, these candidate vaccine strains showed strong protective efficacy
against AHSV infection in an IFNAR/mouse model.
Among closely related orbiviruses (Reoviridae family), such asbluetongue virus (BTV), epizootic hemorrhagic disease virus
(EHDV), and African horse sickness (AHS) virus (AHSV), AHSV
is known to cause the most severe morbidity and mortality in
infected animals. In susceptible horses, AHSV can cause different
forms of disease ranging from mild fever to an acute form, char-
acterized by high fever, depression, respiratory symptoms, severe
weight loss, rough hair, lethargy, and apathy, and mortality
reaches up to 95% (1). Although AHS is endemic to sub-Saharan
Africa, occasional outbreaks which had significant social and eco-
nomic impacts were reported in North Africa, Pakistan, India,
Spain, and Portugal. These three orbiviruses are transmitted by
midges of Culicoides species, which circulate throughout Europe
and the United States, thus increasing the geography of the poten-
tial risk of an AHSV outbreak, similar to the risk from BTV and
EHDV (2). The genome sequence of AHSV is sufficiently diver-
gent from the genome sequences of BTV and EHDV (3), and
unlike BTV, which has 27 serotypes, only 9 serotypes of AHSV
(AHSV serotype 1 [AHSV1] to AHSV9) have been distinguished
to date. Vaccination with a polyvalent live-attenuated vaccine
(LAV) against AHSV is currently used to control the disease in
Africa. However, this vaccine is considered unsafe due to adverse
side effects and because it often causes viremia and has the poten-
tial of reassortment with wild-type AHSV strains, resulting in the
possibility of spread of virus infection (4). Therefore, rationally
designed safe AHSV vaccine candidates are currently being devel-
oped but have not been marketed yet (5–10).
AHSV is a nonenveloped virus containing 10 double-stranded
RNA (dsRNA) segments (S1 to S10). The outer capsid is com-
posed of two major structural proteins, VP2 and VP5. The sero-
type-determining protein VP2 is the most variable viral protein
and themajor target of the protective immune response. The core
particle consists of two concentric layers: the surface VP7 layer
and the inner VP3 layer that encloses the genome of 10 dsRNA
segments and a replicase complex of three enzymes, VP1, VP4,
and VP6 (11). Comparisons of the sequences of capsid proteins
VP2, VP3, VP5, and VP7 of BTV serotype 10 (BTV10) with those
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from EHDV serotype 1 and AHSV4 have revealed the close struc-
tural relationship between these viruses: the inner core proteins,
VP3 and VP7, are the most conserved, whereas the outermost
proteins, VP2 andVP5, are themost variable (12). Previous struc-
tural studies of BTVhave revealed the atomic-level details for BTV
particle organization (13, 14), and it is expected that the AHSV
architecture has a structural organization similar to that of BTV
(15). However, at the level of individual proteins, only the struc-
ture of a top domain of VP7 has been reported for AHSV4 (16);
therefore, a molecular understanding of the structure-function
relationship ofAHSVproteins is not available and structure-based
rational vaccine design for AHSV is not currently possible.
In the past decade, reverse genetics (RG) technology has revo-
lutionized the understanding of BTV replication (17, 18) and
pathogenesis (19, 20) and greatly advanced the development of
vaccine technologies (21, 22). The RG technology for AHSV
strains has been demonstrated (23, 24) but needs significant im-
provement to increase the efficiency of virus recovery. A similar
RG-based approach has been developed for live-attenuated
AHSV4, providing a promising approach for vaccine develop-
ment (7).
The RG technology for BTV, where defective VP6 (encoded by
S9) was complemented by a VP6-expressing cell line, made possi-
ble the rapid generation of disabled infectious single cycle (DISC)
vaccine strains (22). This strategy has been demonstrated to be
efficient for different serotypes by reassortment of the two variable
RNA segments that encode the outer capsid proteinsVP2 andVP5
with the remaining eight RNA segments of BTV1, including the
single-strandedRNA (ssRNA) that encodes the defectiveVP6. Im-
portantly, DISC viruses showed efficient replication in the com-
plemented cell line but no virus production in any othermamma-
lian or insect cell lines. The vaccination of cattle and sheep with
such DISC viruses either singly or in a cocktail followed by chal-
lenge with virulent BTV strains showed neither a clinical reaction
nor any detectable viremia (25).
Based on this highly promising DISC BTV vaccine technology,
we aimed to improve and adapt it for the generation of AHSV
vaccine strains. First, we employed an RG system for AHSV1 for
the production of high titers of viruses solely in a complemented
cell line. Once we achieved the defective AHSV1 strain, we utilized
this strain as a backbone to develop defective-virus vaccines spe-
cific for all nine serotypes. However, in spite of the structural
similarity between BTV and AHSV, it became clear that unlike the
results obtainedwith the BTV serotypes, the exchange of only VP2
and VP5 of the other serotypes with the respective segments of
AHSV1 did not generate viable reassortant viruses, indicating that
the other proteins are not highly conserved between AHSV1 and
the different serotypes. It was therefore necessary to exchange ad-
ditional segments for certain serotypes. These vaccine strains were
then tested for their protective efficacies in type I interferon recep-
tor (IFNAR)-knockout (IFNAR/) mice.When vaccinatedmice
were challenged with two virulent strains of AHSV, complete pro-
tection against homologous infection was achieved, demonstrat-
ing the suitability of the vaccine strains as vaccine candidates.
MATERIALS AND METHODS
Cells and viruses. BSR cells (subclones of BHK-21 cells) weremaintained
inDulbeccomodifiedEaglemedium(DMEM; Sigma) supplementedwith
5% fetal bovine serum (FBS; Invitrogen). The stable cell line BSR-VP6was
grown in DMEM–5% FBS supplemented with 7.5 g/ml of puromycin
(Sigma). Equine dermal (E. Derm) cells (NBL-6, ATCC CCL-57) were
cultured in Eagle minimum essential medium (MEM; Sigma) supple-
mented with 10% FBS and 1% nonessential amino acids. Mammalian cell
lines were cultured at 37°C in a 5% CO2 humidified atmosphere. Insect
KC cells, derived fromCulicoidesmidges (26), weremaintained at 28°C in
Schneider’s insect medium supplemented with 10% FBS.
AHSV serotypes 1 to 9 were kindly supplied by S. Zientara (ANSES,
France). All AHSV serotypes were passaged once in BSR cells, titrated, and
used for subsequent experiments. The AHSV4 challenge strain was kindly
provided by José Manuel Sánchez-Vizcaíno (Universidad Complutense
de Madrid, Spain).
Plasmids. For the AHSV1 RG system, the coding regions of the
corresponding segments were inserted in the pCAG-PM vector (18)
using AflII and PacI restriction sites. The corresponding expression
plasmids were designated pCAG-AHSV1VP1, pCAG-AHSV1VP3,
pCAG-AHSV1VP4, pCAG-AHSV1VP6, pCAG-AHSV1VP7, pCAG-
AHSV1NS1, and pCAG-AHSV1NS2 and confirmed by sequencing. T7
plasmids carrying AHSV transcripts were generated using a sequence-
independent cloning system as previously described (17). Briefly,
genomic dsRNA was ligated to a self-annealing primer before reverse
transcription (RT)-PCR amplification with an adaptor primer. Each
cDNA amplified from AHSV segments was cloned into the pUC19 vector
and sequenced.
An AHSV1mutant (S9multistop) containing 11 stop codons (TAA or
TGA) throughout the S9 gene was created by gene assembly and the in-
troduction ofmutations at positions 288 to 304 (3 stop codons and anNS4
frameshift), 377 to 385 (3 stop codons), 590 to 607 (3 stop codons), and
872 to 877 (2 stop codons), and the sequence was confirmed.
Development of the BSR-VP6 cell line constitutively expressing
AHSV1 VP6.A complemented cell line expressing AHSV1 VP6, the BSR-
VP6 cell line, was generated as described previously (18) with somemod-
ifications. Briefly, BSR cells were transfected by electroporation at 240 V
and 975 F with an AHSV1 VP6-expressing vector, pCAG-AHSV1VP6.
After electroporation, a suspension of cells was seeded onto 150-mm cul-
ture plates and VP6-expressing colonies were selected in the presence of
7.5g/ml of puromycin. Surviving clones were tested by immunoblotting
analysis using polyclonal guinea pig antiserum raised against AHSV6VP6,
whichwas cross-reactive with AHSV1VP6. The best-expressing clonewas
used for the recovery of VP6-defective viruses.
Recovery of wild-type (wt) AHSV1 fromT7 RNAs. The T7 promoter
and exact 3= end containing DNAs were used as the templates in equimo-
lar proportions to produce amixture of 10 capped T7 RNA transcripts for
AHSV1 using an mMESSAGE mMACHINE T7 Ultra kit (Ambion) ac-
cording to themanufacturer’s instructions. For the recovery of a strain by
RG (the recAHSV1 strain), BSR cells at 50% confluence in 12-well plates
were transfected with a set of expression plasmids carrying the genes for
AHSV1 VP1, VP3, VP4, VP6, VP7, NS1, and NS2 in different combina-
tions (80 ng of each plasmid per well). At 16 h posttransfection (hpt), cells
were transfected for a second time with a total of 500 ng of all 10 capped
RNA transcripts. To assess the RNA infectivity, at 4 h after the second
transfection the monolayers were overlaid with 1.5% low-temperature
agarose (catalog number A9045; Sigma) in DMEM containing 1% FBS
and incubated for 2 to 3 days at 35°C until the formation of plaques.
Alternatively, to collect recovered viruses, the transfection medium was
replaced with DMEM containing 1% FBS and incubation was continued
for 2 to 3 days until the appearance of a cytopathic effect.
Recovery of def-AHSV from T7 RNAs. For recovery of VP6/NS4-
deficient AHSV1 (def-AHSV1), BSR-VP6 cells at 50% confluence in 12-
well plates were transfected with 5 pCAG plasmids carrying the genes for
VP1, VP3, VP4, VP6, and NS2 (80 ng each), followed by a second trans-
fection at 16 hpt with a total of 500 ng of 10 capped AHSV1 RNA tran-
scripts: those for S1 to S8, S10, and S9multistop. To obtain reassortant
def-AHSVs, several segments were used to replace parental AHSV1. Each
defective virus was plaque purified and titrated on BSR-VP6 cells. To
assess stability, each defective virus was passaged at least 5 times in BSR-
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VP6 cells at amultiplicity of infection (MOI) of 0.1. Analysis of the dsRNA
profile and RT-PCR/sequencing were used to confirm the integrity of the
introduced AHSV segments.
In vitro growth kinetics of AHSV. The growth kinetics of wt AHSV
anddefective viruseswere determined inBSR-VP6, BSR,KC, andE.Derm
cells following infection for 1.5 h at MOIs of 0.1, 5, 2.5, and 10, respec-
tively. After infection, the inoculum was removed and the cells were
washed twice with medium supplemented with 1% FBS. At 0, 24, 48, and
72 h postinfection (hpi), the supernatant was harvested and the titer in
BSR-VP6 cells was determined by plaque assay and expressed as the num-
ber of PFUpermilliliter. Each experiment was performed in triplicate and
repeated twice. Three strains of wt AHSV1 were used in this experiment:
recAHSV1 (obtained by RG from exact copies of T7 RNAs), wt AHSV1
(obtained from secondBSR cell passage of the original AHSV1 stock), and
AHSVKC (virus passaged twice in KC cells at an MOI of 0.1). All three
AHSV stocks showed similar results (data not shown); therefore, data for
only one strain (recAHSV1) are presented.
Mouse vaccination. Thirty IFNAR/ mice with a C57BL/6 mouse
genetic backgroundwere obtained from the specific-pathogen-free breed-
ing unit of the Friedrich-Loeffler Institut (Germany) and assigned to 5
groups; male and female animals were distributed equally. Six mice each
were immunized subcutaneously twice 3 weeks apart with 106 PFU (100
l) of def-AHSV1 or def-AHSV4 and were also challenged by the same
route 21 days after the second immunization with 105 50% tissue culture
infective doses (TCID50) in 100 l of either AHSV serotype 1 (the def-
AHSV1-immunized group) or AHSV serotype 4 (the def-AHSV4-immu-
nized group). Twelve mice were mock vaccinated with phosphate-buff-
ered saline (PBS); six of them were infected with AHSV1, and six of them
were infected with AHSV4. Six further mice were kept as controls. The
experimental protocol was reviewed by a state ethics commission (Lande-
samt für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklen-
burg-Vorpommern [LALLF]) and has been approved by the competent
authority (reference number LALLF M-V/TSD/7221.3-1.1-058/10).
All mice were weighed daily for 10 days after vaccination and infection
and examined for clinical signs, which included weight loss, rough hair,
lethargy, and apathy; but no neurological signs, such as ataxia, paresis of
one or more legs, or paralysis, were observed, as reported previously (27).
Animals showing severe symptomswere immediately euthanized, and the
remaining infected and untreated control animals were euthanized at 2 or
3 weeks after challenge. Blood samples were obtained from all mice at 3, 7,
and 10 days after infection. At autopsy, blood, spleen, liver, and brain
samples were taken, and the organ samples were homogenized in 1 ml
serum-freeMEM.RNA from20l blood or 100l tissue homogenatewas
extracted using a KingFisher 96 Flex purification system (Thermo Scien-
tific, Braunschweig, Germany) in combination with a MagAttract virus
miniM48 kit (Qiagen,Hilden,Germany) according to themanufacturers’
instructions and analyzed by a VP7-based real-time RT-quantitative PCR
(qPCR) assay (28) combinedwith an internal control system targeting the
beta-actin housekeeping gene (29).
RESULTS
Establishment of reverse genetics for AHSV.An efficient RG sys-
tem offers a rapid approach for manipulation of the viral genome
that allows the molecular mechanisms of viral genes and gene
products to be understood. The previously published AHSV RG
system used transfection of a mixture of two different serotypes,
namely, six plasmids expressing AHSV6, followed by 10 T7 RNA
transcripts of AHSV4, in order to recover viable virus (23). How-
ever, this combination was found to be insufficient for molecular
manipulations due to the low efficiency of recovery of virus, which
was present at titers of less than 106 PFU/ml. Therefore, it was
necessary to identify a well-replicating AHSV serotype with uni-
form large plaques for virus recovery by the RG system. All ninewt
AHSV serotypes were then tested on BSR cells to assess virus titers
and plaque phenotypes (Fig. 1). Three distinct groups of AHSV
serotypes were observed: a large defined plaque phenotype with
high titers (AHSV1), a medium plaque phenotype with high titers
(AHSV3, -5, and -6), and a small/undefined plaque phenotype
(AHSV2, -4, -7, -8, and -9) with low titers. Four well-replicating
AHSV serotypes (AHSV1, -3, -5, and -6) were analyzed for genetic
stability via sequencing of several plaque-purified isolates, and
three (AHSV3, -5, and -6) showed high genetic diversity. To avoid
any complication, plaque-purified AHSV1, which exhibited a
large uniformplaque phenotype andhigh titers (5 108 PFU/ml),
was considered to be the most suitable for use in an RG system.
The recovery of full copies of the 10AHSV1RNA segments was
performed by a sequence-independent method as described pre-
viously (17). For each of the 10 segments, a T7 promoter-derived
plasmid with the exact 3= end was generated to produce 10 capped
T7 RNA transcripts. The protein-coding sequences of VP1, VP3,
VP4, VP6, VP7, NS1, and NS2, which form the primary replicase
complex, were used to generate expression plasmids under the
control of the pCAG promoter (24). For the RG system, we tested
several conditions to mimic the preformation of the primary rep-
lication complex. The transfection of 3 to 7 expression plasmids
followed by the transfection of exact copies of 10 T7 RNA tran-
scripts was performed. A combination of 5 expression plasmids
(expressing VP1, VP3, VP4, VP6, and NS2) was found to be suf-
FIG 1 Genetic and phenotypic analysis of AHSV serotypes. The plaque morphology in BSR cells infected with the indicated AHSV serotypes and incubated for
48 h is shown. The viruses were divided into groups with large (AHSV1), medium (AHSV3, -5, and -6), and small (AHSV2, -4, -7, -8, and -9) plaque phenotypes.
The strategy for developing the RG backbone virus (AHSV1) and the recovery of selected segments for the other 8 AHSV serotypes is shown below.
AHSV vaccine
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ficient to generate high numbers of AHSV plaques and was used
throughout the subsequent experiments (Fig. 2A). When an iso-
lated plaque (recAHSV1) was amplified in BSR cells, virus titers
were as high as 4 108 PFU/ml, equivalent to that of the wt virus.
Both the plaque morphology and genomic dsRNA profile were
similar to those of the wt AHSV1 (Fig. 2B). These data demon-
strate that the efficient AHSV1 RG system requires primary trans-
fection of subcore andNS2 expression plasmids followed by trans-
fection of 10 exact copies of the ssRNA transcripts.
Generationof a stable cell line expressing an essential geneof
AHSV1. The efficient RG system should be suitable for the gener-
ation of targeted, highly defective AHSV strains, facilitating func-
tional and structural studies without the requirement of a high-
containment environment. It has previously been shown that
VP6, a product of S9, is involved in both ssRNA packaging and
helicase activity (30). Therefore, we decided to develop VP6-defi-
cient viruses, which required the generation of a cell line comple-
mentedwithVP6. The ability of trans-complementation of VP6 in
the RG system of the related virus BTV has led to the development
of VP6-deficient mutant viruses that are able to replicate in the
complemented cell line but not in BSR or insect KC cells (18, 22).
Therefore, we created a BSR cell line expressing AHSV1 VP6 (the
BSR-VP6 cell line) by electroporation of BSR cells with pCAG-
AHSV1VP6, followed by puromycin selection. The selected clone
stably expressed VP6 for 30 passages at low dilutions (Fig. 3A).
In addition to VP6, S9 also encodes a minor nonstructural
protein,NS4,which is dispensable for BTV replication inBSR cells
(31). To construct VP6/NS4-deficient AHSV1 (def-AHSV1), we
introduced multiple nucleotide changes in S9 of AHSV1. Instead
of the use of deletions reported for VP6-deficient BTVs (22), we
introduced 11 stop codons (TAA or TGA) throughout the S9 gene
(S9multistop), disrupting the open reading frames (ORFs) of VP6
and NS4 but retaining the length of the S9 RNA, thus minimizing
the genetic pressure on defective AHSV1 recovery and replication.
The absence of VP6 in def-AHSV1 was expected to be compen-
sated for by the complemented cell line.
Using the newly developed BSR-VP6 complemented cell line,
def-AHSV1 could be recovered by transfection of 5 expression
plasmids followed by transfection of 10 capped T7 RNA tran-
scripts, where S9 was replaced by the S9multistop segment. After
the second transfection, agar-overlaid monolayers were used to
assess RNA infectivity, whichwas comparable to that ofwtAHSV1
(Fig. 3B). Recovered virus was plaque purified using the BSR-VP6
cell line and amplified once titers of 1 108 PFU/ml (titrated on
the complemented BSR-VP6 cell line) were reached. The plaque
morphology (Fig. 3B) and analysis of genomic dsRNA segments
FIG 2 Establishment of reverse genetics system for AHSV1. (A) Minimum requirements for primary replication of AHSV1. BSR cells were transfected in
triplicate with the set of indicated expression plasmids (PC, polymerase complex proteins VP1, VP4, and VP6), followed by a second transfection with 10 capped
AHSV1 T7-derived transcripts (S1 to S10). (Top) The bar chart shows the number of plaques per microgram of 10 T7 RNAs; (bottom) the plaque morphology
of each combination indicated above is shown. The bars represent the average standard deviation. (B) (Top) Purified genomic dsRNA profiles of wt AHSV1
and RG-recovered virus (recAHSV1) analyzed on a 9% nondenaturing polyacrylamide gel. The positions of the genomic dsRNA segments are indicated on the
right. (Bottom) Plaque formation of wt and recAHSV1 stocks in BSR cells.
FIG 3 Stable cell line (BSR-VP6 cells) expressing VP6 to complement defec-
tive AHSV1. (A) The complemented cell line expressing AHSV1 VP6 was
generated, and one selected clone was passaged 30 times at a 1:20 dilution.
Equal numbers of cells from the indicated passages were analyzed by immu-
noblotting using a VP6-specific antibody. Normal BSR cells were used as a
control. (B) Plaque morphology of defective virus (def-AHSV1) in BSR-VP6
cells recovered by the RG system. Mock- and recAHSV1-infected cells were
used as controls under the same conditions used for def-AHSV1.
Lulla et al.
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showed the expected dsRNA profile (Fig. 4C), confirming that
AHSV VP6 can be efficiently complemented and NS4 is dispens-
able for AHSV replication in BSR cells.
Efficient assembly of heterologous AHSV particles requires
reassortment of several segments. The ability of orbiviruses to
reassort provides the possibility to coat the conserved replicase
complex or inner core with the outer capsid, thereby resulting in
serotype-specific particles. Such particles may have broad appli-
cation spectra, for example, as vaccine candidates or safe plat-
forms for structural and molecular studies. It has previously been
demonstrated that the exchange of AHSV VP2 only can lower the
reassortant virus titers up to 3 log units (7), resulting in impaired
replication and/or particle instability. Therefore, we aimed to uti-
lize def-AHSV1 as a backbone to achievewell-replicating defective
strains of all 8 other AHSV serotypes (AHSV2 to AHSV9) by ex-
changing combinations of different segments.
Initially, exact copies of segments S2 (VP2), S6 (VP5), S7
(VP7), S3 (VP3), and S10 (NS3/NS3A) of each serotype were
cloned and sequenced. Amino acid sequence analysis of themajor
structural proteins of the nine AHSV serotypes revealed the in-
creases in the degree of conservation in the expected order: VP2
was the least conserved (identity, 13 to 71%; similarity, 27 to
84%), followed by VP5 (identity, 75 to 99%; similarity, 90 to
99%) and then VP7 and VP3, which were the most conserved
(identity, 98%; similarity, 99%). To produce T7 RNA tran-
scripts, exact copies of T7 DNA clones of genomic segments were
generated as described above.
For defective-virus recovery, BSR-VP6 cells were transfected
with the complete set of T7 RNAs of AHSV1, where S9 was re-
placed by S9multistop and, depending on the serotype, the com-
binations S2-S6, S2-S6-S7, S2-S6-S7-S3, or S2-S6-S7-S3-S10 were
used to replace the equivalent segments of def-AHSV1. The crite-
ria for the selection of defective viruses were the plaque size (clear
plaques after 2 to 3 days of incubation at 35°C) and the final titer of
the plaque-purified viruses determined using the BSR-VP6 cell
line (107 to 108 PFU/ml). These requirements were chosen tomin-
imize any possible pressure to avoid recombination and instability
of themodified dsRNAgenome. As expected, the exchange of only
S2 (VP2) resulted in either no virus recovery (def-AHSV2, -3, and
-5) or very poor recovery with titers in the range of 2 103 to 5
105 (def-AHSV4, -6, -7, -8, and -9). These observations are con-
sistent with those for previously published AHSV reassortants
based on S2 exchange (7). To develop stable and high-titer defec-
tive viruses of the different serotypes, replacement of two outer
capsid proteins with def-AHSV1 was not sufficient for all sero-
types. While well-replicating def-AHSV8 and def-AHSV9 could
be achieved by the reassortment with only 2 segments (S2 and S6)
encoding the outer shell proteins VP2 and VP5, def-AHSV3 and
def-AHSV4were achieved onlywhen, in addition to S2 and S6, the
homologous S7, encoding the scaffolding VP7 protein for deposi-
tion of VP2 and VP5, was also exchanged (Table 1). Three addi-
tional serotypeswere created by reassortmentwith 4 segments (S2,
S6, S7, S3), resulting in def-AHSV5, def-AHSV6, and def-AHSV7.
This set was created by complete replacement of the major struc-
tural protein shell. Further, to generate well-replicating (in BSR-
VP6 cells) reassortant def-AHSV2, five segments (S2, S6, S7, S3,
FIG 4 Reassortant-defective AHSV variants. (A) Schematic representation of def-AHSV1 backbone defective virus depicting the S9multistop segment. (B)
Schematic representation of reassortant-defective virusesAHSV2 toAHSV9. The segments exchanged in order to achieve high titers and a large plaque phenotype
in the BSR-VP6 cell line are indicated on top. The cartoons of defective AHSV particles illustrate the origins of fourmajor structural proteins to be AHSV1 (blue)
or another serotype (red). The red dsRNA segments indicate the exchanged segment (S2, S3, S6, S7, and S10). The serotypes of each reassortment group obtained
are indicated below. (C) The pattern of genomic dsRNA purified from the BSR-VP6 cell line infected with wt AHSV1, recAHSV1, and defective AHSV variants
(5th passage at anMOI of 0.1 on the BSR-VP6 cell line) was analyzed on a 9% nondenaturing polyacrylamide gel. The positions of the genomic dsRNA segments
are indicated on the right. The wt S9 dsRNA position is indicated on the left, whereas the S9multistop dsRNA of defective AHSV variants is indicated by green
arrowheads. The red arrows on the gel correspond to the exchanged segments used for the recovery of defective AHSV variants.
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S10) had to be replaced to achieve high titers on the comple-
mented BSR-VP6 cell line (Table 1). In each case, when these
required combinations of segments were not replaced, defective
viruses (AHSV2, 3-, -4, -5, -6, and -7) were poorly recovered and
these viruses exhibited a small plaque phenotype and low titers,
ranging from 104 to 106 PFU/ml. Therefore, these were excluded
from the subsequent studies. The schematic representation of all
selected defective viruses is summarized in Fig. 4A and B. All 9
defective viruses were passaged 5 times at an MOI of 0.1 in the
complementing BSR-VP6 cell line, confirming at each step that
none of the tested stocks was able to replicate on wild-type BSR
cells. To assess the stability and integrity of reassortant-defective
viruses, dsRNA was extracted from stocks of the initial virus re-
covery and the final (fifth) passage. Each dsRNA sample exhibited
the correct mobility (Fig. 4C). Further, RT-PCR and sequencing
also validated the authenticity of the RNA segments in all defec-
tive-virus strains.
Defective AHSVs do not grow in AHSV-susceptible cell lines
but yield high titers in the complemented cell line.Todetermine
the growth kinetics of each of the defective viruses, complemented
BSR-VP6 cells were infected with each virus at a lowMOI, and the
virus titers were determined at 24, 48, and 72 hpi. Similar to wt
AHSV1, all 9 defective viruses were capable of replication in the
complemented BSR-VP6 cells, reaching titers in the range of 107
to 108 PFU/ml and forming plaques at 2 to 3 days postinfection
(Fig. 5A). Each def-AHSV variant was propagated five times at a
lowMOI in complemented cells (BSR-VP6 cells). Aliquots of each
passage corresponding to 5 107 to 1.5 108 particles were then
tested in wt BSR cells to ensure the defective property. As ex-
pected, there was no virus growth, confirming the safety of the
def-AHSV variants.
To confirm that both parental def-AHSV1 and the eight reas-
sortant-defective viruses were incapable of growth in normal cells,
the growth kinetics of each defective virus were evaluated by in-
TABLE 1 RNA segment requirements for the recovery of nine defective
AHSV serotypes
def-AHSV
serotype
Exchange of heterologous segment:
Virus titer
(PFU/ml)
S2
(VP2)
S3
(VP3)
S6
(VP5)
S7
(VP7)
S10
(NS3)
def-AHSV1a 2 107 to 9 107
def-AHSV2      1 107 to 4 107
def-AHSV3    5 107 to 7 107
def-AHSV4    3 107 to 1 108
def-AHSV5     2 107 to 3 107
def-AHSV6     2 107 to 3 107
def-AHSV7     2 107 to 3 107
def-AHSV8   8 107 to 1 108
def-AHSV9   7 107 to 1 108
a def-AHSV1 is the parental strain.
FIG5 Growth ofVP6-deficient viruses inmammalian and insect cell lines. (A)Virus growth kinetics in the complementedBSR-VP6 cell line. BSR-VP6 cells were
infectedwith the indicated viruses at anMOI of 0.1. The titer was analyzed by plaque assay onBSR-VP6 cells at 0, 24, 48, and 72 hpi. (B toD)Virus growth kinetics
in normal BSR (B), insect KC (C), and E. Derm (D) cells. The three cell lines were infected at anMOI of 5 (BSR cells), 2.5 (KC cells), and 10 (E. Derm cells). The
titer was analyzed by plaque assay on BSR-VP6 cells at 0, 24, 48, and 72 hpi.
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fecting three different normal cell lines (BSR, Culicoides KC cells,
and E. Derm cells) at a highMOI andmeasuring the virus titers at
24, 48, and 72 hpi. The results demonstrated that these defective
viruses (def-AHSV1 to def-AHSV9) were not able to grow in any
of these three cell lines (Fig. 5B to D). To ensure that there was no
delayed replication, all infected cells were incubated for an addi-
tional 7 days; however, no signs of infection were detected (data
not shown).When the results are taken together, we conclude that
all nine defective viruses grew to high titers (between 3 107 and
1 108 PFU/ml) in the complemented cell line (Table 1) but did
not produce viable virions in normal BSR, KC, and E. Derm cells.
Considering that the standard vaccination dose per horse is 106 to
107 virus particles, for a quadrivalent vaccine the maximum in-
jected volume will not exceed 0.5 to 1 ml, since 2  107 cells
infectedwith each def-AHSV serotype should provide at least75
to 200 doses, suggesting that such productivity is appropriate for
clinical applications and mass production. These results demon-
strate a great potential for these defective viruses to be used as safe
AHSV vaccine candidates.
Defective AHSV1 and AHSV4 efficiently protect IFNAR/
mice from homologous infection. As a proof of principle, def-
AHSV1 and reassortant def-AHSV4 were assessed for their pro-
tective efficacy against AHSV infection in an animal model. Since
adult interferon-knockout (IFNAR/) mice had been shown to
be susceptible to AHSV (27) and proved to be an appropriate
model with which to test for AHSV vaccine efficacy in horses (10),
two groups of mice were immunized twice with 106 PFU of either
def-AHSV1 or def-AHSV4. No adverse side effects were observed
after vaccination, and the bodyweights of immunized and control
animals showed no significant differences (a maximum 10% vari-
ation was observed for all groups). At 3 weeks after the second
immunization, vaccinated and control animals were challenged
subcutaneously with virulent AHSV1 or AHSV4. Protection indi-
cators included body weight measurements, survival times, and
blood and tissue AHSV-specific RNA levels. The group of 6 con-
trol mice, which were not vaccinated but which were challenged
with AHSV4, started to lose weight from day 3 or 4 postchallenge
onwards. Four animals were euthanized at day 7 after infection
(because of severe weight loss, rough hair, and apathetic behav-
ior), and the two remaining mice were euthanized on day 8. The
nonvaccinatedmouse group infected with AHSV1, representing a
less virulent serotype, showed no clinical signs. Also, groups of
mice vaccinated with either def-AHSV1 or def-AHSV4 showed no
clinical signs (Fig. 6A).
The levels of viremia, determined by analysis of the amount of
AHSV-specific RNA present in blood, were measured in all mice
at 3, 7, and 10 days after infection. No AHSV-specific RNA was
detected in any mock-infected mice. Mice infected with AHSV4
had significantly higher AHSVRNA levels thanmice infectedwith
AHSV1 (Fig. 6B). These data correlated with the mouse survival
times (Fig. 6A), suggesting that AHSV1 represents a less virulent
serotype. In immunized animal groups, the levels of viremia were
significantly reduced (Fig. 6B). The analysis of AHSV-specific
RNA was combined with an internal control system targeting the
beta-actin housekeeping gene, which was present in all collected
blood samples (threshold cycle [CT] values, 26 to 32).
Spleen, liver, and brain tissue samples were taken for RNA
extraction, and RNA was quantified as described in Materials and
Methods. Consistent with the previous data (Fig. 6A and B), high
loads of AHSVRNAweremeasured in all organs of nonvaccinated
mice with AHSV4 infection, whereas the analyzed organs of the
AHSV1-infected group demonstrated from lowAHSVRNA levels
to no AHSV RNA. As expected, vaccination with def-AHSV1 and
def-AHSV4 prior to homologous AHSV challenge led to a signif-
icant reduction of AHSV RNA levels in mouse organs (Fig. 6C).
Nonimmunized mice infected with AHSV1 and AHSV4 showed
detectable levels of AHSV-specific RNA, but AHSV1-infected
mice hadnomortality orweight loss, in contrast to the findings for
AHSV4-infected mice. For this reason, the AHSV-specific RNA
level was chosen as the main protection indicator for analysis of
the potency of the vaccine candidates.
DISCUSSION
African horse sickness remains an actual threat to the species of
equidae in Africa and countries surrounding the Mediterranean.
Although live-attenuated polyvalent vaccines protecting against
almost all AHSV serotypes, except serotypes 5 and 9, are commer-
cially available, these vaccine strains have a high risk of reassort-
ment with field isolates, which results in the introduction of new
virus serotypes into countries where AHSV is not endemic (32).
Therefore, in the last 2 decades, various attempts have been made
to develop safe and efficacious AHSV vaccines; however, to date
none of these has been developed into a commercial product. For
successful vaccine preparation, in addition to safety and efficacy, it
is essential that someother criteria also bemet, including technical
simplicity and reproducibility, ease of scaling up of production,
downstream processing of the manufactured vaccine, and most
importantly, cost-effective vaccine manufacture, particularly for
animal vaccines. Moreover, vaccines that could allow the differ-
entiation of infected from vaccinated animals (DIVA) are also
highly desirable. Although subunit vaccines based on purified
proteins are compliant with the need for DIVA and safe, they
generally do not provide sufficient and long-lasting protection
and their production is costly. Orbivirus-like particles are safe and
provide sufficient protection but require complex preparation
methods and suffer from low yields and problems with reproduc-
ibility. Although attenuated virus-based chimeras created by the
exchange of outer capsid protein VP2 alone or in combination
with VP5 have good immunological potential, so far they have
demonstrated significant variability in virus titers (7), which are
often as low as 105 to 106 PFU/ml, which precludes their further
development into a cost-efficient product. Therefore, in this
study, we prioritized the virus productivity parameters to over-
come these deficiencies for the generation of AHSV vaccine can-
didates.
Based on previous research on orbiviruses, we considered the
creation of replication-deficient virus particles, which enclose an
efficient replicase of a backbone virus coated with immunogenic
capsid proteins from all AHSV serotypes, to be the most promis-
ing strategy. For this purpose, the most efficiently replicating
plaque-purifiedAHSV1 variantwas first selected as it provided the
highest titers and had a defined large plaque phenotype. Second,
the genome segments of this AHSV1 variant were subcloned and
sequenced, and an efficient RG system, alongwith optimized virus
recovery parameters, was established. It was found that the dou-
ble-transfection approach, in which cells were first transfected
with DNA expression vectors, which provided high-level expres-
sion of the primary replication complex components of 5 pro-
teins, followed by transfection with in vitro-cotranscribed RNAs
representing exact copies of the virus segments, was the most ef-
AHSV vaccine
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ficient method for AHSV recovery, similar to that previously re-
ported for BTV (33). To create replication-defective virus, we tar-
geted disruption of the ORF of the essential replicative enzyme
VP6, as well as the overlapping ORF of the less well-studied NS4
protein, in the coding region of segment S9 of AHSV1 by intro-
ducingmultiple stop codons. Notably, mutations introduced into
the S9multistop segment should be sufficient to allow differenti-
ation of infected from vaccinated animals by quantitative RT-
PCR; this, however, needs to be confirmed in future experiments.
To support the replication of a defective virus, it was necessary to
establish a complementedBSR cell line expressing functional VP6.
These cells were highly efficient in supporting the propagation of
defective AHSV1. Therefore, AHSV1 was considered suitable as a
backbone for the generation of defective virus strains for the re-
FIG 6 Protection of IFNAR/mice by def-AHSV1 and def-AHSV4 vaccination from homologous challenge infection. (A) Survival plots of adult IFNAR/
mice (6 per group) immunized with 106 PFU of def-AHSV1 or def-AHSV4 (i.e., vaccinated [vac]) and challenged (i.e., infected [inf]) with 105 TCID50 of the
homologouswt AHSV1 orwt AHSV4 strain. (B andC)RNAemia in blood (B) and organs (spleen, liver, brain) (C) of the indicated groups of animals is presented
as a graph of invertedCT values obtained by RT-qPCR.CT values higher than 40 were considered negative. Each dot corresponds to one analyzed animal sample.
Cq, quantification cycle.
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maining eight serotypes (AHSV2 to AHSV9) by exchanging the
RNA segments encoding serotype-determining capsid proteins of
the other serotypes. Similar strategies to create replication-defi-
cient virus strains have been previously reported for BTV (22, 25),
adenovirus (34), and herpes simplex virus and other viruses (re-
viewed in reference 39). Such defective viruses have an advantage
as vaccines because their initial infection site mimics replicating
virus, thus providing a strong and specific immune response.
Since during viral infection the majority of a neutralizing im-
mune response is based on the VP2 protein, it would be logical to
assume that exchange of the corresponding segment would be
sufficient. However, since the productivity of a vaccine strains is
also critical, we sought to optimize conditions to generate vaccine
strains. We found that for eight AHSV serotypes (AHSV2 to
AHSV9) the rescue of corresponding viruses using an established
RG systemwas possible for some serotypes but that the titers of the
viral stockswere unacceptably lower (below5 105 PFU/ml) than
those of the parental virus. Such a low titer of the rescued virus not
only would impede its further development into a cost-efficient
vaccine candidate but also is indicative of the problems associated
with virus assembly, dissemination, and, possibly, genetic stabil-
ity. It can be expected that swapping the large, most variable RNA
segment, segment S2, to alter the serotype of the virus particlemay
have a number of consequences. The orbivirus particle is made up
of three concentric layers of proteins, whereas VP2makes contacts
with the outer capsid protein VP5 and the inner capsid protein
VP7. Therefore, amino acid changes in the replaced VP2 may
disturb its interactions with other capsid proteins, thus influenc-
ing the stability of the assembled virion. Additionally, orbiviral
RNA segments not only need to interact with each other (36) but
also may interact with the packaging protein during assembly, so
the integrity of the native S2 can be crucial. Therefore, variations
at the nucleotide sequence level may also result in a reduced effi-
ciency of core assembly for heterologous virus. To this end, cur-
rent knowledge about nucleotide-level requirements for RNA
packaging and atomic-level structural details about AHSV virion
organization is clearly lagging behind, precluding the rational de-
sign and optimization of reassortant virus particles. Therefore, we
used a semirational approach by replacing S2 (VP2) along with S5
(VP5), S2 with S5 and S7 (VP7), and S2-S5-S7 with S3 (VP3) or
S2-S5-S7-S3 and S10, as S10 is also highly variable amongdifferent
AHSV serotypes. We assumed that the advantage of the replace-
ment of S10 can be 2-fold, because S10 RNA has been reported to
be especially important during RNA packaging (36), whereas its
ORF encodes the NS3 protein, which is implicated in the virus
budding process (35). By testing various combinations, we se-
lected virus variants that efficiently replicated to titers equivalent
to those of the wt virus. Interestingly, the number of segments
needed to be exchanged in the backbone virus differed for differ-
ent serotypes, with the extreme case beingAHSV2,which required
the exchange of five segments, including S10 (NS3). These data are
in agreement with previously published reports on BTV, where
interaction betweenVP2 andNS3has been shown to be important
for efficient virus egress (37). However, the possibility that RNA-
RNA interactions are involved in the efficiency of reassortment
between AHSV serotypes should also be considered.
Since adult IFNAR/ mice infected by AHSV show clinical
disease and pathogenesis and have successfully been used for
AHSV vaccine efficacy studies and the same vaccines have also
conferred protection in horses, IFNAR/mice are an appropri-
atemodel for the evaluation of the protective efficacy of the defec-
tive viruses (10, 27).When two different defective viruses, includ-
ing one reassortant-defective virus, were assessed, both vaccinated
groups of mice demonstrated significantly decreased levels of
viremia, in contrast to the control nonvaccinated groups, which
showed high levels of viremia and/or clinical signs. Although these
data are highly encouraging, further vaccination/challenge exper-
iments with different combinations of serotypes will need to be
assessed using not only IFNAR/mice but also horses.
The live-attenuated AHSV vaccines have been extensively used
in South Africa for several decades. More recently, one of the LAV
strains, AHSV4LP, which has a deletion of NS3/NS3A, was em-
ployed as a potential vaccine development platform (7). However,
a recent report on another RNA virus has demonstrated the rever-
sion to virulence of an attenuated severe acute respiratory syn-
drome coronavirus lacking E protein after it was propagated in
mice (38). Therefore, the in vitro complementation of a missing
protein would represent a safer AHSV vaccine platform with a
minimized genetic pressure toward the reversion to virulence.
Notably, in this study, we avoided deletion of the genes but dis-
rupted the ORF of AHSV S9, coding for VP6 and NS4, by intro-
ducing multiple stop codons. Multiple passages of the vaccine
strains in a complemented cell line did not reveal any changes in
the mutated S9, strongly suggesting that the mutated ORF is un-
likely to revert. Also, our results have demonstrated that all nine
defective AHSVs were able to replicate in the complemented cell
line to titers similar to those of the wt AHSV serotypes. Most
importantly, defective viruses were unable to propagate in normal
cells, whether they were of mammalian or insect origin. Unlike
live-attenuated vaccine strains, the def-AHSV vaccine candidates
are replication deficient in normal cells, and their activity is lim-
ited to the primary expression only of viral proteins, making the
risks of recombination with circulating field strains minimal. As a
result, such vaccines provide a safer option for horses than the
current live-attenuated virus vaccines and have equivalent or im-
proved protective efficiency.
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